AMGN Today - Aug 09: EMA Backs Repatha Use

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

AMGN Today - Aug 09: EMA Backs Repatha Use

無料で聴く

ポッドキャストの詳細を見る

Hey there! It’s Joey, your friendly long-time investor here, breaking down the day for you. Today, we’re talking about Amgen, and guess what? It was a green day! The stock was up about 1.5%. Not a huge jump, but still nice to see some green.

So, what went down today? Amgen's stock had a bit of a bounce thanks to some positive news. The big highlight? The European Medicines Agency gave a thumbs up for broader use of their drug Repatha in high-risk patients. That’s a big deal, right? When a regulatory body backs a product, it can really pump some confidence into the stock.

Now, why the buzz? Well, this EMA nod could open up a whole new market for Repatha, which is already used to lower cholesterol. Analysts are getting excited too and have been hiking their price targets for the stock. It’s like when your favorite band drops a surprise album — it just gets everyone hyped up.

But it wasn’t all sunshine and rainbows today. There was some news that Nancy Grygiel, Amgen’s Senior VP and Chief Commercial Officer, sold off about $1.19 million worth of stock. That one stung a bit for investors. When insiders sell, people start to wonder what they know that we don’t. But hey, maybe it’s just a personal financial move. Who knows?

Looking ahead, Amgen’s got to keep that momentum going. They’ve had some solid earnings recently and updates on their pipeline, so there’s a lot to watch. But for now, it’s all about that EMA approval and the potential it brings.

Alright, that’s the scoop for today! Just remember, this is all for fun and info, not financial advice. Catch you later!

まだレビューはありません